[en] Peripheral blood glucose, plasma insulin and C-peptide levels were investigated after giving a standardized breakfast (500 kcal, 60 g carbohydrates) to 10 nonobese Type 2 diabetic patients previously treated by diet alone. Each patient received at random, at 1 week intervals, either 5 mg glipizide (meal + glipizide) or a placebo (meal alone) 30 min before breakfast. Basal values of blood glucose, plasma insulin and C-peptide were similar on both occasions. After meal + glipizide, the blood glucose increase was sharply limited whereas the rise in plasma insulin was steeper and reached twice as high a level. In contrast, the rise in plasma C-peptide was similar in both conditions. Consequently, the areas under the curves (0-300 min) showed a marked reduction in blood glucose after meal + glipizide (2289 +/- 149 versus 3101 +/- 169 mmol X min/1; 2p less than 0.001), associated with a significant increase in plasma insulin (14219 +/- 3261 versus 7591 +/- 1173 microU X min/ml; 2p less than 0.025) but no significant change in plasma C-peptide (342 +/- 45 versus 326 +/- 34 pmol X min/ml; N.S.). The insulin/C-peptide molar ratio was thus significantly increased after meal + glipizide (0.41 +/- 0.06 versus 0.23 +/- 0.04 at the 60th min; 2p less than 0.02). The dissociation between the responses of insulin and C-peptide suggests that a single dose of 5 mg glipizide in Type 2 diabetic subjects may enhance availability of peripheral insulin by extrapancreatic mechanism(s). This phenomenon may result in a higher circulating level of the hormone and therefore represent a further mode of action of sulphonylureas.(ABSTRACT TRUNCATED AT 250 WORDS)
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Luyckx, A. S.
Language :
English
Title :
Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
Yalow R.S., Black H., Villazon M., Berson S.A. (1960) Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes 9:356-362.
Lebovitz H.E., Feinglos M.N., Bucholtz H.K., Lebovitz F.L. (1977) Potentiation of insulin action: a probable mechanism for the anti-diabetic action of sulfonylurea drugs. J Clin Endocrinol Metab 45:601-604.
Marshall A., Gingerich R.L., Wright P.H. (1970) Hepatic effect of sulfonylureas. Metabolism 19:1046-1052.
Feldman J.M., Lebovitz H.E. (1969) Appraisal of the extrapancreatic actions of sulfonylureas. Arch Int Med 123:314-322.
Almér L.O., Johansson E., Melander A., Wåhlin-Boll (1982) Influence of sulfonylureas on the secretion, disposal and effect of insulin. European Journal of Clinical Pharmacology 22:27-32.
Lefèbvre P.J., Luyckx (1976) The breakfast tolerance test: a return to physiology. Diab Metab , Paris; 2:15-19.
Hales C.N., Randle P.J. (1963) Immunoassay of insulin with insulin antibody precipitate. Biochem J 88:137-146.
Heding L.G. (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548.
Vailati G., Caputo G., Mandelli V., Pagani G., Montini M., Sacchetti G. (1975) Pharmacological studies in diabetic patients: a comparison of glipizide and glibenclamide. The Journal of Clinical Pharmacology 15:60-65.
Sartor G., Schersten B., Melander A. (1978) Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients. Acta Med Scand 203:211-214.
Wåhlin-Boll E., Melander A., Sartor G., Schersten B. (1980) Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. European Journal of Clinical Pharmacology 18:279-283.
Hed R., Nygren A., Röjdmark R., Sundblad L., Wiechel K.L. (1979) Insulin in portal, hepatic and peripheral venous blood after glucose, tolbutamide and glipizide stimulation. Indication of insulin release from peripheral tissues. Acta Med Scand 205:221-225.
Eriksson M., Erwald R., Hed R., Nygren A., Patricny J., Röjdmark S., Sundblad L., Wiechel K.L. (1976) Immunoreactive insulin in portal and hepatic venous blood in patients with insuloma. Acta Med Scand 200:145-149.
Kaiser N., Tur-Sinai A., Cerasi E. Possible extrapancreatic action of glibenclamide: sparing of circulating insulin by inhibition of its degradation , K.G.M.M., Alberti, T., Ogada, J.A., Aluoch, E.N., Mngola, 11th Congress of the International Diabetes Federation. ICS no 577, Excerpta Medica, Amsterdam Princeton London Geneva Tokyo Melbourne; 1982, 92.
Bottermann P., Zilker T. (1978) Blood glucose, insulin and C-peptide levels during a test meal without and with sulfonylureas in diabetics. Diabetologia , Abstract; 15:221-222.
Brogard J.M., Pinget M., Leconte A., Dorner M. (1982) Effet à moyen terme (3 mois) du traitement sulfamidé hypoglycémiant (gliclazide) sur la sécrétion insulinique de diabétiques non insulinodépendants. Rev Méd Int 3:379-387.
Bodansky H.J., Medback S., Cudworth A.G., Rees L.H., De Silva R.S. (1982) Long term improvement in insulin response with gliclazide treatment. Diab Metab , Paris; 8:319-322.
Beck-Nielsen H., Pedersen O., Lindskov H.O. (1979) Increased insulin sensitivity and cellular insulin binding to obese diabetics following treatment with glibenclamide. Acta Endocrinol 90:451-462.
Greenfield, Doberne L., Rosenthal M., Schulz B., Widstrom A., Reaven G.M. (1982) Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Diabetes 31:307-312.